Loading clinical trials...
Loading clinical trials...
The purpose of the study is to assess self-reported side effects and neurocognitive (brain, mood and thinking) functioning among patients treated with commercial axi-cel therapy.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Moffitt Cancer Center
Tampa, Florida, United States
Start Date
March 10, 2020
Primary Completion Date
July 14, 2023
Completion Date
July 31, 2023
Last Updated
March 2, 2026
60
ACTUAL participants
Handgrip strength test
OTHER
Neuropsychological Assessment - Wechsler Test of Adult Reading (WTAR)
BEHAVIORAL
Neuropsychological Assessment - Repeatable Battery for the Assessment of Status (RBANS)
BEHAVIORAL
Neuropsychological Assessment - Color Trails
BEHAVIORAL
Neuropsychological Assessment -Stroop Color and Word Test
BEHAVIORAL
Patient Reported Outcomes Measurement Information System-29 (PROMIS-29) Questionnaire
BEHAVIORAL
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire
BEHAVIORAL
Quality of Life (EQ-5D-5L) Questionnaire
BEHAVIORAL
PROMIS Cognitive Function 4a Questionnaire
BEHAVIORAL
Comprehensive Score for Financial Toxicity (COST) measure
BEHAVIORAL
Lead Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Collaborators
NCT05006716
NCT06026319
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions